Table 7.
Fine and Gray regression analysis to determine risk factors for leukemic transformation in patients with myeloproliferative neoplasm (N=351).
| Univariate analysis | Multivariate analysis | ||||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | ||
| Factors at diagnosis | |||||||
| Age >60 yr | 2.90 | 0.75–11.30 | 0.125 | - | - | - | |
| Female | 1.98 | 0.62–6.34 | 0.247 | - | - | - | |
| Palpable splenomegaly | 2.79 | 0.80–9.87 | 0.140 | - | - | - | |
| WBC >11.0×109/L | 1.86 | 0.57–6.06 | 0.304 | - | - | - | |
| Monocyte >1.0×109/L | 4.05 | 1.23–13.39 | 0.022 | 3.22 | 0.69–14.68 | 0.135 | |
| Platelet >1,000×109/L | 2.44 | 0.77–7.73 | 0.128 | - | - | - | |
| LDH >1.5×UNL | 2.74 | 0.81–9.26 | 0.105 | - | - | - | |
| Positive JAK2V617F | 3.40 | 0.41–28.40 | 0.258 | - | - | - | |
| Positive CALR mutation | 0.99 | 0.26–2.11 | 0.579 | - | - | - | |
| PMF | 3.51 | 0.80–15.44 | 0.096 | - | - | - | |
| Abnormal karyotype | 5.60 | 1.10–28.59 | 0.038 | 3.62 | 0.41–31.14 | 0.241 | |
| Thrombosis before or at diagnosis | 1.26 | 0.34–4.66 | 0.730 | - | - | - | |
| Hydroxyurea treatment | 1.98 | 0.43–9.11 | 0.381 | - | - | - | |
Abbreviations: CI, confidence interval; HR, hazard ratio; LDH, lactate dehydrogenase; PMF, overt primary myelofibrosis; UNL, upper normal limit.